BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saito T, Maruyama J, Nagata N, Isono M, Okuya K, Takadate Y, Kida Y, Miyamoto H, Mori-Kajihara A, Hattori T, Furuyama W, Ogawa S, Iida S, Takada A. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses. Viruses 2020;12:E923. [PMID: 32842671 DOI: 10.3390/v12090923] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Lee HN, McWilliams IL, Lewkowicz AP, Engel K, Ireland DDC, Kelley-Baker L, Thacker S, Piccardo P, Manangeeswaran M, Verthelyi D. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model. Emerg Microbes Infect 2021;10:2076-89. [PMID: 34674613 DOI: 10.1080/22221751.2021.1997075] [Reference Citation Analysis]
2 Soltan MA, Abdulsahib WK, Amer M, Refaat AM, Bagalagel AA, Diri RM, Albogami S, Fayad E, Eid RA, Sharaf SMA, Elhady SS, Darwish KM, Eldeen MA. Mining of Marburg Virus Proteome for Designing an Epitope-Based Vaccine. Front Immunol 2022;13:907481. [DOI: 10.3389/fimmu.2022.907481] [Reference Citation Analysis]
3 Salazar-garcía M, Acosta-contreras S, Rodríguez-martínez G, Cruz-rangel A, Flores-alanis A, Patiño-lópez G, Luna-pineda VM. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Front Microbiol 2022;12:817200. [DOI: 10.3389/fmicb.2021.817200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]